163
EXHIBIT 31.2
------------
This is an Exhibit to the Form 20-F of Sinovac Biotech Ltd.
-----------------------------------------------------------
Attached find the following materials:
Certification of Disclosure in Sinovac Biotech Ltd.'s
-----------------------------------------------------
Annual Report by Lily Wang
--------------------------
End of Exhibit 31.2
---------
164
Certification of Disclosure in
------------------------------
Sinovac Biotech Ltd.'s Annual Report
------------------------------------
In connection with the Annual Report on Form 20-F of Sinovac Biotech Ltd.
(the "Company") for the period ended December 31, 2003, as filed with the
Securities and Exchange Commission on June 30, 2004, (the "Report"), I, Lily
Wang, Chief Financial Officer of the Company, hereby certify, pursuant to the
Sarbanes-Oxley Act of 2002, that:
(1) I have reviewed this Report being filed;
(2) Based on my knowledge, this Report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
Report;
(3) Based on my knowledge, the financial statements, and other financial
information included in this Report, fairly present in all material
respects the financial condition, results of operations and cash flows of
the Company as of, and for, the periods presented in this Report;
(4) The Company's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-14 and 15d-14) for the Company and have:
(i) designed such disclosure controls and procedures to ensure that
material information relating to the Company, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this Report is being
prepared;
(ii) evaluated the effectiveness of the Company's disclosure controls and
procedures as of a date within 90 days prior to the filing date of
this Report ( the "Evaluation Date"); and
(iii) presented in this Report our conclusions about the effectiveness of
the disclosure controls and procedures based on their evaluation as of
the Evaluation Date;
(5) The Company's other certifying officer and I have disclosed, based on our
most recent evaluation, to the Company's auditors and the audit committee
of the Company's board of directors (or persons fulfilling the equivalent
function):
(i) all significant deficiencies in the design or operation of internal
controls which could adversely affect the Company's ability to record,
165
process, summarize and report financial data and have identified for
the Company's auditors any material weaknesses in internal controls;
and
(ii) any fraud, whether or not material, that involves management or other
employees who have a significant role in the Company's internal
controls; and
(6) The Company's other certifying officer and I have indicated in this Report
whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions
with regard to significant deficiencies and material weaknesses.
Date: June 30, 2004 /s/ Lily Wang
-----------------------------------
Name: Lily Wang
Title: Chief Financial Officer